Home › NDC Lookup › J-codes › A9573
A9573

A9573 – Inj, gadopiclenol, 1 ml · NDC Crosswalk & Billing Units

HCPCS Level II J-code · Medicare Part B drug billing
J-code ● 11 NDCs crosswalked per 1 ML $3.152/unit ASP+6%

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

📋 A9573 summary

A9573 is a HCPCS Level II J-code used to bill gadopiclenol, 1 ml, billed per 1 ML. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with A9573: Elucirem*, Vueway, Elucirem

Code A9573 Billing unit 1 ML Payment limit $3.152/unit NDC-Crosswalk 11 Quarter Q3 2026 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeA9573
DescriptorInj, gadopiclenol, 1 ml
Billing unit1 ML
Payment limit / unit$3.152
Est. ASP / unit$2.974 est.
Mapped NDCs11
Data periodQ3 2026
Last updated2026-09-20

💊 About Gadopiclenol DRUG GUIDE

Elucirem and Vueway are both indicated for use with MRI to detect and visualize lesions (abnormal areas) with abnormal blood vessel activity.

Both products are approved for use in adults and pediatric patients, including term newborns.The areas they help visualize include the central nervous system (brain, spine, and surrounding tissues) and the body (head and neck, chest, abdomen, pelvis, and musculoskeletal system).

These are imaging aids — they make MRI scans clearer — not treatments for an underlying disease.

Read the full Gadopiclenol drug guide →
Clinical overview from our editorial drug guide for Gadopiclenol. For billing reference, see the sections above.

🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026

📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$3.152
Est. ASP / unit
$2.974 est.
Est. after 2% sequester
$3.089
HCPCS dosage
1 ML
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of A9573 = 1 ml. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under A9573 WITH EST. MEDICARE PAY

11 NDCs map to A9573. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($3.152/unit) × that package's bill units.
NDC (11-digit)DrugLabelerPackageStrength Bill units Est. pay / pkg NADAC / unit StatusSource
00270-7015-46 Vueway Gadopiclenol 485.1 mg/mL INJECTION BRACCO 25 VIAL, PHARMACY BULK PACKAGE in 1 CASE (... 485.1 mg/mL 750 $2,364.00 — ● Active CMS ASP
00270-7015-48 Vueway Gadopiclenol 485.1 mg/mL INJECTION BRACCO 25 VIAL, PHARMACY BULK PACKAGE in 1 CASE (... 485.1 mg/mL 1,250 $3,940.00 — ● Active CMS ASP
00270-7020-38 Vueway Gadopiclenol 485.1 mg/mL INJECTION BRACCO 10 VIAL, SINGLE-DOSE in 1 CASE (0270-7020-... 485.1 mg/mL 30 $94.56 — ● Active CMS ASP
00270-7025-40 Vueway Gadopiclenol 485.1 mg/mL INJECTION BRACCO 10 VIAL, SINGLE-DOSE in 1 CASE (0270-7025-... 485.1 mg/mL 75 $236.40 — ● Active CMS ASP
00270-7030-42 Vueway Gadopiclenol 485.1 mg/mL INJECTION BRACCO 10 VIAL, SINGLE-DOSE in 1 CASE (0270-7030-... 485.1 mg/mL 100 $315.20 — ● Active CMS ASP
67684-4230-02 ELUCIREM gadopiclenol 485.1 mg/mL INJECTION Guerbet 10 VIAL in 1 CARTON (67684-4230-2) / 3 mL... 485.1 mg/mL 30 $94.56 — ● Active CMS ASP
67684-4231-02 ELUCIREM gadopiclenol 485.1 mg/mL INJECTION Guerbet 10 VIAL in 1 CARTON (67684-4231-2) / 7.5... 485.1 mg/mL 75 $236.40 — ● Active CMS ASP
67684-4232-02 ELUCIREM gadopiclenol 485.1 mg/mL INJECTION Guerbet 10 VIAL in 1 CARTON (67684-4232-2) / 10 m... 485.1 mg/mL 100 $315.20 — ● Active CMS ASP
67684-4240-02 ELUCIREM gadopiclenol 485.1 mg/mL INJECTION Guerbet 10 SYRINGE in 1 CARTON (67684-4240-2) / 7... 485.1 mg/mL 75 $236.40 — ● Active CMS ASP
67684-4241-02 ELUCIREM gadopiclenol 485.1 mg/mL INJECTION Guerbet 10 SYRINGE in 1 CARTON (67684-4241-2) / 1... 485.1 mg/mL 100 $315.20 — ● Active CMS ASP
67684-4250-04 ELUCIREM gadopiclenol 485.1 mg/mL INJECTION Guerbet 25 VIAL, PHARMACY BULK PACKAGE in 1 CARTON... 485.1 mg/mL 1,250 $3,940.00 — ● Active CMS ASP
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)

Period
Total Part B spend
$647.3K
Claims
23,837
Beneficiaries
22,964
Spend / beneficiary
$28.19
Spend / claim
$27.16
Trend by period
Where A9573 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #414 of 824
#409 KIMYRSA J2406 $713.3K #410 CYTOGAM J0850 $665.1K #411 ADACEL TDAP* 90715 $664.3K #412 VEKLURY J0248 $659.4K #413 SUSTOL J1627 $653.9K #414 ELUCIREM* A9573 $647.3K #415 AMNIO-MAXX OR LITE P... Q4239 $644.5K #416 KEDRAB 90377 $641.8K #417 CAREPATCH PER SQ CM*... Q4236 $638.5K #418 TRI MEMBRANE WRAP, P... Q4344 $610.6K #419 TRIVISC J7329 $610K
Total claims — #94 of 824
#89 KISUNLA J0175 25,188 #90 NPLATE J2802 24,900 #91 SYNVISC-ONE* J7325 24,623 #92 BUPIVACAINE HCL* J0665 24,071 #93 BCG (TICE STRAIN)(J9... J9030 23,898 #94 ELUCIREM* A9573 23,837 #95 OHTUVAYRE J7601 22,564 #96 LEUCOVORIN CALCIUM J0640 21,924 #97 ABRAXANE* J9264 21,913 #98 GRANISETRON HCL J1626 21,847 #99 DEXTENZA J1096 21,748

Full breakdown by period (2)
PeriodTotal spendBeneficiariesClaims$/beneficiary$/claim
2026 (Q1) $647.3K 22,964 23,837 $28.19 $27.16
2025 (Q1-Q4) $2.07M 62,945 70,812 $32.82 $29.18
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

📈 Medicare Part B claims detail CMS PSPS · 2024

Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$1.2M
Medicare paid
$933.2K
Submitted services
272,805
Denial rate
17.0%
Allowed / service
$5.30
Submitted charges
$6.32M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.

🗺️ Where A9573 is utilized CMS · BY PROVIDER · 2024

Medicare Part B services for this code by the rendering provider's state — 210,869 services across 37 states & territories in 2024 (CMS reports include DC and U.S. territories). Switch to per 100k to compare states fairly regardless of population. Hover or tap a state for its top ZIP codes.
Hover or tap a state to see its numbers + top ZIP codes.
Per-capita = services ÷ 2023 state population × 100,000 (so high-population states aren't automatically "hotter"). Counts reflect the provider's location, not the patient's. Providers with fewer than 11 patients are hidden by CMS for privacy, so totals run low and per-100k can be noisy in small states — read this as relative geography, not exact counts. Source: CMS Medicare Physician & Other Practitioners — by Provider and Service, 2024.

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Not available in current dataset
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-09-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk
11 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

  • A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
  • Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
  • Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
  • Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
  • The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
  • Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ A9573 billing FAQ

What is HCPCS code A9573?
A9573 is a HCPCS Level II J-code used to bill Inj, gadopiclenol, 1 ml under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for A9573?
One unit of A9573 represents 1 ML. Report the number of units equal to the dose administered divided by 1 ML.
How many units of A9573 should I bill?
Divide the dose administered by the code's unit size (1 ML) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for A9573?
The Medicare Part B payment limit is $3.152 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $3.089 per unit. Payment limits are revised quarterly.
Which NDCs bill under A9573?
11 NDCs currently map to A9573 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean A9573 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.